BetterLife FSHD health and research platform
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study creates a patient-driven health and research platform for people with FSHD. It aims to collect information to better understand the condition and improve future research and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a clinical or genetic diagnosis of FSHD, or you have a family history of FSHD and are showing symptoms.
- You are at least 1 year old.
- You live in the United States or its territories.
- If you are 18 or older, you must be willing and able to provide consent.
- If you are under 18, you must be willing to provide assent (when applicable) and have a parent or guardian register and consent for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry aims to collect health information from people in the UK who have facioscapulohumeral muscular dystrophy (FSHD). It helps researchers better understand the disease and plan future studies.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This study looks at muscle MRI images and walking patterns (3D gait analysis) in people with FSHD. It helps researchers understand how the disease affects movement and muscle over time.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
This study explores how facioscapulohumeral muscular dystrophy (FSHD) affects your daily life, health, and living situation. It does not test a new treatment, but aims to better understand the challenges patients face.
Hear when a new FSH Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.